The  primary  objective  of  this  study  was  to  assess  the  weight  controlling properties  of  different  compounds  in  their  available  products  in  Egyptian market  used  for  the  treatment  of  obesity  in  dietary  obese  female  rates  in comparison with orlistat as a reference FDA approved anti-obesity drug. Eighty female  rats  were  allocated  into  8  groups,  ten  rats  per  each  group.  Ten  rats received  normal  palatable  diet  (NPD)  for  five  months;  the  remaining  rats received high fat diet (HFD) for three months to establish diet-induced obesity. Rats  receiving  HFD  were  divided  equally  into  seven  groups.  One  group returned to normal diet and the other groups returned to normal diet and treated with  orlistat  (10  mg/kg/day)  or  garcinia  cambogia  extract  (400  mg/kg/day)  or combination of garcinia cambogia extract (400 mg/kg/day) and chromium (28 μg/kg/day)  or      chromium  (28  μg/kg/day)  or  chromium  (80  μg/kg/day)  or combination of garcinia cambogia extract (400 mg/kg/day) and chromium (80 μg/kg/day) for additional two months. Feeding with HFD induced a significant increase  in  body  weight  of  rats  as  well  as  serum  glucose,  insulin  resistance, serum  lipids,  leptin,  adipose  tissue  index,  atherosclerosis  index  and  oxidative stress marker such as MDA and visfatin as compared to normal feeding group. These  measurements  were  suppressed  by  orlistst,  garcinia  cambogia  extract, chromium,  combination  of  garcinia  cambogia  extract  and  chromium  with different  extend.  Our  data  ensures  the  findings  that  garcinia  cambogia, chromium  and  their  combination  possess  weight  controlling  and  insulin sensitizing properties. Combination of garcinia cambogia and chromium can be used  as  alternative  to  orlistat  for treatment  of  obesity  to  overcome  its  adverse effect.